TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05965687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normobaric Hyperoxia
Description: Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal oxygen
Description: For nasal oxygen group, patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study: NCT04700917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Internet-Based CBT
Study: NCT06530576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide and methotrexate
Description: Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
Study: NCT04754958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersion in virtual reality using Nordic Neurolab(™) Visual System
Description: In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
Study: NCT06576102

Intervention type: OTHER
Intervention: Persisting SARS-CoV-2 infection
Description: Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients defined as the persistence or the recurrence of symptoms and signs (fever, dyspnea, hypoxemia, changes on chest-X ray or CT scan) and positive SARS-CoV-2 PCR ≥ 21 days after the time 0 (day of the first test positive for SARS-CoV-2 infection)
Study: NCT06575920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing excercizes
Description: The intervention comprised six sessions. The first week involved obtaining informed consent, taking measurements and providing a brief introduction to breath and coherent breathing exercises. This was followed by four weekly sessions, each consisting of 90 minutes combining lectures and breathing exercises. At the final session, measurements and feasibility data were collected.
Study: NCT06575335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triphala Tooth Wipe
Description: The wipes will be used 1 hour after meal time, twice daily for consecutively 7 days. The sachet seal will be opened, the wipe will be taken out and rest of the sachet sealed again. The wipes will be unfolded and wrapped around index finger of right hand and all surfaces of child's teeth, gums, roof of the mouth and tongue will be cleaned.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Tooth Wipe
Description: Same as triphala tooth wipe
Study: NCT05445635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iriscope
Description: The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iriscope
Description: The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iriscope
Description: The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
Study: NCT05645640

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Village doctor-led tailored health management
Description: Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life.
Study: NCT05424510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: 500 ml of Ringer's Lactate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV line
Description: Placing of an IV line before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV line
Description: Placing of an IV line before surgery
Study: NCT05728827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training + Anti-gravity treadmill
Description: Blood flow restriction training is administered via straps applied to the proximal limb with the possibility to adjust the applied occlusion pressure in order to prevent venous return leaving the arterial flow partially free. The consequent blood pooling causes a reduction in tissue saturation with oxidative stress and an increased growth factors secretion. The intervention will be applied while walking/running on the anti-gravity treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-gravity treadmill
Description: The intervention will be applied walking/running on the anti-gravity treadmill.
Study: NCT05536232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Low carbohydrate diet under 75 g per day
Study: NCT06185179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be distributed in 500mg pills.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be distributed in pill form
Study: NCT05965687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis(rt-PA)
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Study: NCT05954195

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high intensity interval training
Description: high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
Study: NCT05047198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Catheter Ablation for VT
Description: Currently standard of care involves surgical resection of myocardial scarring in structural heart disease. Imaging is performed to identify culprit areas for ablation, pre procedural imaging involves echocardiography, CT scanning and PET imaging to assess cardiac function, ischemia, inflammation and scarring. Radiofrequency energy is delivered via catheter to the targets and is performed under sedation or anesthesia using multiple catheters placed in the heart while the patient is anticoagulated. A conventional approach will be used advancing multiple catheters via femoral veins and/or arteries under a combination of fluoroscopic, ultrasound and electroanatomic guidance. Ablation targets include an arrhythmogenic focus or the critical isthmus of the VT circuit and/ or substrate identified on preprocedural imaging or low voltage areas, scar, identified during endocardial mapping. CA procedures for VT are often long, averaging approximately 5 hours .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment - Non-Invasive Radio Ablation for VT
Description: Patients undergoing a non-invasive RA procedure for VT similarly require medical stabilization and multimodal imaging prior to treatment. A non-invasive electrophysiology study is performed under light sedation using ECGi mapping. This procedure requires only the placement of an IV cannula for light sedation, uses the ICD to stimulate VT which is mapped in real time using the ECGi mapping system. The multimodal imaging data is digitally fused and combined with the ECGi data to identify the VT circuit(s) and to attain the targets for radio-ablation. This analogue process is performed off-line by a physician team. The treatment plan is sent for alignment on a 4D planning CT performed with breath holding in the radiotherapy suite. Final treatment targets are reviewed by the local treating team and discussed with our collaborators remotely. Thereafter the patient is booked for a 15 minute out-patient radiotherapy treatment performed on a standard linear accelerator.
Study: NCT04684121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin® gel (200 μM)
Description: Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.
Study: NCT05954195

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high intensity interval training
Description: high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
Study: NCT06016452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorophyllin
Description: Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorophyllin
Description: Chlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food coloring agent.
Study: NCT05217342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic therapy
Description: Standard diuretic therapy according to the current guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Description: Standard diuretic therapy according to the current guidelines
Study: NCT05385120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary Portocaval Shunt
Description: In Temorary Portocaval Shunt Group (TPCS group), Hilar dissection( division of Hepatic artery, Bileduct) is followed by temporary portocaval shunt formation during recipient Hepatectomy.
Study: NCT05310474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Glider
Description: The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Glider
Description: The purpose of this study is to study the efficacy of a remote range of motion monitor, the Knee Glider, alongside a patient engagement platform, Force Therapeutics, on clinical improvements and cost following primary TKA.
Study: NCT06285721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: tACS is a non-invasive brain stimulation technique which involves the application of a low intensity electric current between two or more surface electrodes. tACS uses stimulation with a current alternating at a specific frequency that can entrain endogenous neuronal oscillations by inducing neural synchronization. The administration of tACS is proposed to phase-lock large populations of neurons in the superficial layers of the cerebral cortex causing neural synchronization in the corresponding frequency, thereby altering connectivity. tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial alternating current stimulation (tACS)
Description: Sham-tACS is a form of non-effective stimulation which can mimic the subjective sensation of active tACS treatment. During sham-tACS, the device will ramp up to 2.0 mA peak-to-peak intensity for 30 seconds, stimulate for 60 seconds and ramp down for 30 seconds, which mimics the sensation of actual tACS stimulation and improves blinding.The sham-tACS will be delivered via a transcranial electrical stimulation (tES) device (Nurostym tES, Brainbox Ltd, United Kingdom). This device has been CE-marked for use as a medical device for the treatment of mental and neurological disorders.
Study: NCT05248932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine bolus
Description: 5 microgram bolus therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cardiometry
Description: cardiac output, stroke volume and fluid responsiveness monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cardiometry
Description: cardiac output, stroke volume and fluid responsiveness monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: 2.5 microgram/min infusion
Study: NCT05374863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) - Active
Description: The NMES will be held for 20 minutes. Biceps musculature and bilateral wrist and finger flexors stimulated. For patients undergoing hemodialysis for fistula in the upper limb, NMES will be performed only in the limb without a fistula. points of points 4 electrodes in each, being 2 points of longitudinal position in the muscular belly of the biceps, and other 2 in the ventral region of the forearm. the parameters: frequency of 80 Hz, pulse frequency of 350 ms, time of 5 seconds and 10 seconds. The possibility will be greater for each patient who will have the contraction. Patients will be instructed to perform an isometric contraction of wrist and finger flexors during electrical stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES) - Sham
Description: It will be performed in the same way as in the experimental group, however, the intensity of the actuality will only reach the sensitive threshold.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise with cycle ergometer
Description: The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with cycle ergometer
Description: The exercise will be performed from the adaptation and positioning of a cycle ergometer (Mini Bike E5 Acte Sports®) in front of the hemodialysis chair. Each session will consist of three phases: duration (5 minutes), conditioning (20 minutes) and cool-down (5 minutes). During the development and cool-down phases, patients will be instructed to maintain a lower exercise intensity, with a level between 1 and 3 on the modified BORG scale. In the conditioning phase, patients will be instructed to slightly increase the intensity of the exercise, levels between 4 and 7 on the modified BORG scale. During exercise, patients will be asked every 5 minutes about the level of effort, and the load on the cycle ergometer will be possible to reach an intensity between 4 and 7 on the modified Borg Scale.
Study: NCT06441968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPV/S-2P
Description: A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPV/S-2P
Description: A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPV/S-2P
Description: A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.
Study: NCT04973605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Once weekly either orally or intravenously
Study: NCT04713631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
Study: NCT04973605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Once weekly either orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered intravenously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered intravenously weekly
Study: NCT05412641

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention - Responsible Fatherhood Programming
Description: Participants receive educational programming to include: 24/7 Dad, Couples Communication I, and a comprehensive program targeting financial literacy/money management.
Study: NCT06562361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-Cys-ATH001
Description: Target dose of 200MBq \[68Ga\]Ga-DOTA-Cys-ATH001 corresponding to a maximum mass dose of 100 µg, administered as an intravenous bolus dose.
Study: NCT06006546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: 100 mcg and 300 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b
Description: 100 mcg and 300 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant 3M-052-AF+Alum
Description: 5 mcg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant 3M-052-AF+Alum
Description: 5 mcg